BLACK WEEKSFlakoni −15% · komplekti −10% · pārējais −5%ar koduBezmaksas piegāde Vācijā no €200

Šī lapa ir tulkota automātiski un var saturēt kļūdas. Vai latviešu valoda ir jūsu dzimtā valoda? Mēs labprāt saņemsim jūsu atsauksmes un labojumus.Sūtīt atsauksmi

The Peptide Desk The Peptide Desk
Torasemid, produkta foto
Medication

Torasemid

Medication

  • Sūtām no Vācijas

Pasūtījums

Vienības cena - Bezmaksas piegāde Vācijā no 200 € Black Weeks laikā
  • DHL ar izsekošanu
  • Diskrēts iepakojums

4.6 no 5 Trustpilot73 atsauksmes

Īsumā

Torasemid skaitļos

Galvenie rādītāji no mūsu leksikona. Velciet punktu pa līkni, lai redzētu, cik daudz paliek pēc vienas devas, pēc aprēķina.

Pilns leksikona ieraksts

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~3.5 hours

Half-life ~3.5 hours
After 7 hours: 25 %
Hour 445 %Hour 725 %Hour 1111.3 %Hour 182.8 %

Simplified model without an absorption phase, half-life from the TPD lexicon. The lexicon gives 3 to 4 hours, we calculate with the middle.

Half-life

about3to4hours

duration 6 to 8 hours

Class
Loop diureticNKCC2 inhibitor
Use
Oral1x daily in the morning
Sizes
10 mg1 size in the shop

Produktam Torasemid vēl nav laboratorijas analīzes. Balsot par toPasūtiet testu, mēs apmaksājam pusiVisas laboratorijas analīzes

Zināšanas

Viss par Torasemid

FAQ

Bieži uzdotie jautājumi

Avoti katrai atbildei: leksikona ieraksts

Vēl ir jautājums?

Rakstiet mums, mūsu komanda jums palīdzēs.

Is torsemide approved?

Yes. ChEMBL lists torsemide with phase 4 as the highest phase and first approval in 1993. ClinicalTrials.gov lists 56 trials with torsemide, as of 26 October 2026.

What did TRANSFORM-HF show?

2,859 patients received torsemide or furosemide after a hospital stay for heart failure. 26.1 versus 26.2 percent died, without difference. Death or hospital stay within 12 months did not differ significantly either (47.3 versus 49.3 percent).

How does absorption differ from furosemide?

Torsemide has a bioavailability of about 80 percent in healthy people, furosemide 26 to 65 percent. In heart failure the peak level was reached after 1.1 instead of 2.4 hours. Absorption varied less.

Why did earlier trials see an advantage?

An open trial with 234 patients found fewer hospital stays for heart failure (17 versus 32 percent). The TORIC observation with 1,377 patients saw lower mortality (2.2 versus 4.5 percent) but was not randomised. The larger randomised trial did not confirm this.

What about potassium?

In TORIC 12.9 percent on torsemide had low potassium at the end, 17.9 percent on furosemide or other diuretics. The groups were not randomised.

Do liver and kidney matter?

Torsemide is mainly broken down in the liver, only about 20 percent appear unchanged in the urine. In liver disease clearance fell to about half. In kidney failure total clearance stayed largely the same according to the review.

Saistītie

Saistītie produkti